Ongoing trials are evaluating targeted therapies (e.g., KRAS, PARP, and mTOR inhibitors), immunotherapies (e.g., checkpoint inhibitors, CAR-T cells, and cancer vaccines), and local treatments like IRE, SBRT, and HIFU. The gene discussed is MTOR; the disease is cancer.